GlassScriptPhysician profile
Nischita Merla
NPI 1629272208
$5,084.14
in general payments reported to CMS, 2019-2025
34 companies · $1,694 in 2025
The $1,694 reported for 2025 was more than what 75% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $148 · 2020: $59.83 · 2021: $695 · 2022: $650 · 2023: $762 · 2024: $1,075 · 2025: $1,694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,531.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,530.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $749.32 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Ardelyx, INC. | $704.50 | 2022-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $666.53 | 2024-2025 | Rezdiffra, Resmetirom |
| Smith+Nephew, INC. | $391.90 | 2021 | |
| Aimmune Therapeutics, INC. | $298.28 | 2024-2025 | Vowst, Zenpep |
| Janssen Biotech, INC. | $258.55 | 2023-2025 | Simponi, Simponi Aria, Stelara |
| Genzyme Corporation | $255.35 | 2022-2025 | |
| Abbvie INC. | $215.48 | 2020-2025 | |
| Phathom Pharmaceuticals, INC. | $205.04 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $164.48 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $160.54 | 2020-2023 | |
| Albireo Pharma, INC. | $85.05 | 2024 | Iqirvo |
| Sanofi-Aventis U.S. LLC | $72.50 | 2019 | |
| Novo Nordisk INC | $72.11 | 2025 | Wegovy |
| Intercept Pharmaceuticals, INC. | $70.19 | 2021-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Conmed Corporation | $64.10 | 2024 | Conmed Hemostasis, Conmed Biopsy |
| Celgene Corporation | $63.70 | 2022-2023 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $59.68 | 2022-2025 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $55.31 | 2025 | Iqirvo |
| Ferring Pharmaceuticals INC. | $54.96 | 2024-2025 | Rebyota |
| Alnylam Pharmaceuticals INC. | $49.84 | 2021-2024 | Oxlumo |
| Pfizer INC. | $48.77 | 2025 | |
| Ironwood Pharmaceuticals, INC | $48.10 | 2021-2023 | Linzess |
| Braintree Laboratories, INC. | $40.91 | 2025 | Sutab, Suflave |
| Cordis US Corp. | $37.46 | 2024 | Infiniti |
| Shionogi INC | $30.13 | 2019 | |
| Celltrion USA INC. | $26.62 | 2025 | Vegzelma |
| Boston Scientific Corporation | $24.22 | 2023 | Watchman Access System |
| Vivus LLC | $23.45 | 2024 | Pancreaze |
| Bard Peripheral Vascular, INC. | $20.28 | 2022 | |
| Janssen Pharmaceuticals, INC | $20.09 | 2019 | |
| Redhill Biopharma INC. | $19.30 | 2022 | |
| Venclose INC. | $16.63 | 2020 | |
| Infobionic, INC | $10.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nischita Merla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.